Core Insights - Golub Capital (GBDC) has provided significant value creation for its shareholders over the past few years, indicating a strong performance in the market [1] - The focus on dividend investing is highlighted as a key strategy for achieving financial freedom, emphasizing its accessibility for investors [1] Company Overview - Golub Capital is recognized for its long-term value creation, with a strong emphasis on dividends as a means of income generation [1] - The company operates in various sectors including tech, real estate, software, finance, and consumer staples, which are also reflected in the investment portfolio [1] Investment Strategy - The article promotes dividend investing as a straightforward approach to building long-term wealth, aiming to demystify the process for potential investors [1] - The author’s experience in M&A and business valuation underlines the importance of financial modeling and due diligence in assessing company health [1]

Core Insights - Fiserv (FISV) has adjusted its expectations in the Q3 2025 earnings release, leading to a negative market reaction and stock penalty [1] Company Overview - Fiserv is identified as a global payment and fintech company [1] Financial Performance - The company has reset its guidance, which has impacted its stock performance negatively [1] Investment Strategy - The investment approach focuses on high-growth opportunities across various industries, emphasizing robust business models and strategic foresight [1] - The discounted cash flow (DCF) valuation methodology is primarily employed, with adaptability to various valuation techniques [1] - Business model frameworks from institutions like Harvard Business School are utilized for in-depth analysis [1] Long-term Growth Potential - The analysis aims to ensure a comprehensive understanding of a company's intrinsic value and strategic positioning within its industry landscape [1] - The focus is on facilitating informed investment decisions with an emphasis on long-term growth potential and risk mitigation [1]

Group 1: Commercial Metals Company (CMC) - Commercial Metals Company is a steel and metal products provider with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 12.5% over the last 60 days [1] - The company has a price-to-earnings ratio (P/E) of 11.35, significantly lower than the industry average of 21.00, and possesses a Value Score of A [1] Group 2: Alcoa Corporation (AA) - Alcoa Corporation produces and sells bauxite, alumina, and aluminum products, also holding a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 5.8% over the last 60 days [2] - Alcoa has a price-to-earnings ratio (P/E) of 11.16, slightly below the industry average of 11.60, and possesses a Value Score of A [2] Group 3: James River Group Holdings, Ltd. (JRVR) - James River Group Holdings is a specialty insurance company with a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 10.5% over the last 60 days [3] - The company has a price-to-earnings ratio (P/E) of 5.46, which is lower than the industry average of 8.30, and possesses a Value Score of B [3]

Core Insights - Seeking Alpha is recognized as a popular platform for dividend investors to research and select funds or equities that meet their income and appreciation needs [1] Group 1 - The Schwab U.S. Dividend Equity ETF is highlighted as a significant investment option for value investors [1] - The author has a background in private credit and commercial real estate mezzanine financing, indicating a strong foundation in financial analysis [1] - The author has experience working with top commercial real estate developers, which may provide valuable insights into market trends and investment opportunities [1]

Core Insights - The article emphasizes the importance of the Zacks Rank system and Style Scores in identifying undervalued stocks, particularly for value investors [1][2][3] Company Analysis: Horace Mann Educators (HMN) - HMN has a Zacks Rank of 2 (Buy) and an A for Value, indicating it is a high-quality value stock [3] - The company's price-to-book (P/B) ratio is 1.37, which is lower than the industry average of 2.20, suggesting it may be undervalued [4] - HMN's P/S ratio is 1.1, which is comparable to the industry's average P/S of 1.11, reinforcing its value proposition [5] - The stock's P/B has fluctuated between 1.09 and 1.43 over the past year, with a median of 1.28 [4] Company Analysis: Ping An Insurance Co. of China (PNGAY) - PNGAY holds a Zacks Rank of 1 (Strong Buy) and an A for Value, indicating strong potential for value investors [6] - The P/B ratio for PNGAY is 0.68, significantly lower than the industry average of 2.20, highlighting its undervaluation [6] - Over the past 52 weeks, PNGAY's P/B has ranged from 0.47 to 0.81, with a median of 0.61 [6] Overall Market Perspective - Both HMN and PNGAY are identified as strong value stocks based on their financial metrics and earnings outlook, suggesting they are likely undervalued in the current market [7]

Core Insights - The article emphasizes the importance of dividend growth investing as a strategy for achieving retirement goals without taking on excessive risk [1] - It highlights the significance of identifying high-quality companies with competitive advantages that ensure future cash flow growth [1] Group 1: Investment Philosophy - The investment approach focuses on building a core portfolio of dividend-paying equities to generate income [1] - The article references Warren Buffet's philosophy on making money while resting, underscoring the need for a strategic investment plan [1] Group 2: Experience and Education - The author has over 20 years of market experience and holds a Bachelor of Management and an MBA, with a focus on corporate and personal finance [1]

Core Insights - The Royce Global Trust is a closed-end fund focused on investing in global equities with a disciplined value approach, aiming for long-term capital growth [7][11]. Performance Summary - As of October 31, 2025, the fund's net asset value (NAV) is $14.78, while the market price is $12.80 [1]. - The average annual total return for the fund is as follows: - One-Month: NAV -1.66%, MKT -1.16% - Year to Date: NAV 17.77%, MKT 19.38% - One-Year: NAV 16.55%, MKT 16.21% - Three-Year: NAV 16.63%, MKT 16.12% - Five-Year: NAV 9.22%, MKT 7.80% - Ten-Year: NAV 9.38%, MKT 9.85% [2]. Portfolio Composition - The fund primarily invests in small-cap and mid-cap companies, with an average market capitalization of $3.168 billion [4]. - The weighted average price-to-earnings (P/E) ratio is 24.9x, and the weighted average price-to-book (P/B) ratio is 3.1x [4][6]. - The top ten positions account for the following percentages of net assets: - Tel Aviv Stock Exchange: 4.6% - Sprott: 3.9% - Protector Forsikring: 3.0% - Alamos Gold Cl. A: 3.0% - Stadio Holdings: 2.5% - APi Group: 2.4% - Phoenix Financial: 1.9% - Littelfuse: 1.9% - TMX Group: 1.8% - Quaker Houghton: 1.8% [8]. - The top five sectors by percentage of net assets are: - Financials: 30.3% - Industrials: 26.9% - Information Technology: 11.7% - Materials: 10.5% - Cash and Cash Equivalents: 6.0% [8]. Investment Strategy - The fund aims to invest at least 80% of its net assets in equity securities and at least 65% in companies located in at least three countries outside the United States [8].

Core Insights - The competitive dynamic between Eli Lilly and Novo Nordisk is highlighted, with Lilly currently outperforming Novo in execution and earnings expectations [2][3]. - There is a significant valuation gap between the two companies, attributed to Lilly's strong performance and Novo's internal challenges, including a new CEO and a failed acquisition attempt [3][4]. - Analysts suggest that Novo could become a value trap, while Lilly is expected to continue its outperformance in the coming years [5]. Company Performance - Eli Lilly is successfully beating earnings expectations and maintaining strong guidance, while Novo Nordisk has missed expectations and had to lower its forecasts [2]. - Internal issues at Novo, including leadership changes and strategic missteps, are contributing to its struggles in the market [3]. Valuation Perspectives - The valuation disconnect between Lilly and Novo is seen as justified due to Lilly's superior execution [4]. - Analysts recommend looking at other healthcare companies like Pfizer and Merck for value investments, rather than focusing solely on Lilly [4][5]. Investment Opportunities - Beyond the GLP-1 market, analysts identify Disc Medicine, a small-cap biotech in rare hematology, and Gilead Sciences, a leader in HIV treatment, as promising investment opportunities [6][7]. - Gilead's long-acting pre-exposure prophylaxis (PrEP) business and its leadership in cell therapy are noted as key strengths [7].

Core Viewpoint - Investors in the Medical - Dental Supplies sector should consider Conmed (CNMD) and Merit Medical (MMSI) as potential value opportunities, with CNMD appearing to be the superior option based on valuation metrics [1]. Valuation Metrics - Both CNMD and MMSI currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions for both companies [3]. - CNMD has a forward P/E ratio of 9.52, while MMSI has a forward P/E of 23.65, suggesting that CNMD is more attractively priced [5]. - The PEG ratio for CNMD is 1.41, compared to MMSI's PEG ratio of 2.46, indicating that CNMD offers better value relative to its expected earnings growth [5]. - CNMD's P/B ratio is 1.31, while MMSI's P/B ratio is 3.38, further supporting the conclusion that CNMD is undervalued compared to MMSI [6]. - Based on these valuation metrics, CNMD holds a Value grade of A, whereas MMSI has a Value grade of C, reinforcing the view that CNMD is the superior value option [6].

Core Viewpoint - The article emphasizes the importance of value investing and highlights John B. Sanfilippo & Son (JBSS) as a strong value stock currently available in the market [2][3]. Group 1: Value Investing - Value investing is a popular strategy that utilizes fundamental analysis and traditional valuation metrics to identify undervalued stocks [2]. - Zacks has developed a Style Scores system to identify stocks with specific traits, particularly focusing on the "Value" category for value investors [3]. Group 2: John B. Sanfilippo & Son (JBSS) - JBSS holds a Zacks Rank of 1 (Strong Buy) and has received an A grade for Value, indicating it is among the strongest value stocks currently [3]. - The P/S ratio for JBSS is 0.72, which is lower than the industry average P/S of 0.91, suggesting that JBSS may be undervalued [4]. - The combination of JBSS's strong earnings outlook and its valuation metrics positions it as an impressive value stock at this time [5].